You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 93 No. 4, APRIL 1954 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

TOXICITY OF ISONICOTINIC ACID HYDRAZIDES IN PULMONARY TUBERCULOSIS

Toxicity of Isoniazid and Iproniazid Used Alone and in Combination with Streptomycin or p-Aminosalicylic Acid

E. O. COATES, Jr., M.D.; G. L. BRICKMAN, M.D.; G. M. MEADE, M.D.

AMA Arch Intern Med. 1954;93(4):541-549.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

INFORMATION available at the present time concerning the toxicity of isoniazid (isonicotinic acid hydrazide) has shown it to be a relatively safe agent for the treatment of pulmonary tuberculosis.* Although a variety of side-effects have been observed, the majority of these have been of minor importance. However, several reports have drawn attention to occasional severe reactions, in particular, psychoses,{dagger} peripheral neuritis,{ddagger} hemoptyses,6 and pellagra.7 Furthermore, experience with iproniazid has shown it to be considerably more toxic than isoniazid.1

At Trudeau Sanatorium the use of iproniazid for investigation has recently been terminated because of frequent and sometimes severe side-effects, as compared to those observed with isoniazid. Documentation of the specific toxicity observed with each of these drugs, both alone and in combination with streptomycin orp-aminosalicylic acid (PAS), is important for comparison with present and future chemotherapeutic agents. This report presents data on the incidence of side-effects and causes of termination of . . . [Full Text PDF of this Article]


Author Affiliations

TRUDEAU, N. Y.

From the Trudeau Sanatorium, Assistant Medical Director (Dr. Coates), Medical Director (Dr. Meade), and Wunderley Traveling Scholar of the Royal Australasian College of Physicians (Dr. Brinkman).


Footnotes

Isoniazid (Rimifon) and iproniazid (Marsilid) for this study were kindly supplied by Hoffmann-LaRoche, Inc., through the courtesy of Dr. Elmer Sevringhaus, Director of Clinical Research.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1954 American Medical Association. All Rights Reserved.